United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018
This teleconference is also being webcast and can be accessed via
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. [uthr‑g]
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the future of our business, our expectation of long-term success, and our efforts to develop organ transplantation technologies. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission that could cause actual results to differ materially from anticipated results. Such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 24, 2018 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-report-third-quarter-2018-financial-results-before-the-market-opens-on-wednesday-october-31-2018-300736679.html
James Edgemond, (301) 608-9292, firstname.lastname@example.org